Neurocrine Biosciences Inc (NASDAQ:NBIX)
| 119.13 Delayed Data As of May 27 |  +0.22 / +0.19%Today’s Change | 72.14 Today|||52-Week Range 128.29 | +10.83% Year-to-Date |
Latest NBIX News | Press Releases
No recent news for Neurocrine Biosciences Inc.
Today’s Trading
| Previous close | 118.89 |
| Today’s open | 118.06 |
| Day’s range | 112.27 - 119.59 |
| Volume | 1,261,243 |
| Average volume (3 months) | 833,768 |
| Market cap | $11.6B |
Data as of 4:00pm ET, 05/27/2020
Growth & Valuation
| Earnings growth (last year) | +72.61% |
| Earnings growth (this year) | +691.28% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +74.65% |
| P/E ratio | 62.7 |
| Price/Sales | 13.06 |
| Price/Book | 18.09 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TECHBio-Techne Corp | -3.38 | -1.30% |
| EXASExact Sciences Corp | +1.30 | +1.61% |
| IMMUImmunomedics Inc | +0.07 | +0.21% |
| ALLOAllogene Therapeutic... | -0.36 | -0.73% |
Data as of 4:58pm ET, 05/27/2020
Financials
| Next reporting date | July 29, 2020 |
| EPS forecast (this quarter) | $0.70 |
| Annual revenue (last year) | $788.1M |
| Annual profit (last year) | $37.0M |
| Net profit margin | 4.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
